Optimal Management of Adverse Events from Copanlisib in the Treatment of Patients with Non-Hodgkin Lymphomas
ConclusionThere are a number of challenges associated with the use of copanlisib. Infusion-related hypertension and hyperglycemia occur frequently, although they are transient, reversible, and rarely of clinical significance; this report provides guidance as to their management.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Diabetes | Endocrinology | Hypertension | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Toxicology